Kesch, Claudia http://orcid.org/0000-0002-2656-2664
Pantea, Vlad
Soeterik, Timo
Marquis, Alessandro
la Bombarda, Giulia
Morlacco, Allesandro
Barletta, Francesco
Radtke, Jan Philipp
Darr, Christopher
Preisser, Felix
Zattoni, Fabio
Marra, Giancarlo
van den Bergh, Roderik C. N.
Hadaschik, Boris
Gandaglia, Giorgio
,
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 6 July 2022
Accepted: 25 November 2022
First Online: 19 December 2022
Declarations
:
: Claudia Kesch has received consulting fees from Apogepha; has received research funding from Advanced Accelerator Applications (Novartis), and curie therapeutics; and has received compensation for travel from Janssen Pharmaceuticals; Jan Philipp Radtke has received consulting fees from Saegeling Medizintechnik, Advanced Accelerator Applications (Novartis), Beckelmann, Astellas, Bayer, Janssen Pharmaceuticals, MedCom, Philips Invivo, Bender Gruppe, Apogepha, SPL Medical; and has received research funding from Advanced Accelerator Applications (Novartis), and Deutsche Krebshilfe; Boris Hadaschik has had advisory roles for ABX, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen R&D, Lightpoint Medical, Inc., and Pfizer; has received research funding from Astellas, Bristol Myers Squibb, German Research Foundation, Janssen R&D, Novartis and Pfizer; and has received compensation for travel from Astellas, AstraZeneca, and Janssen R&D. The other authors have no competing interests to declare that are relevant to the content of this article.